# Gate Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gate-bioscience

- Industry: Biotechnology
- Headquarters: Brisbane, US
- Website: www.gatebio.com
- Total disclosed funding: $125M
- Latest round: Series B (Nov 13, 2025)
- Investors on record: 6

## About

Based in California, US, and founded in 2021, Gate Bioscience, Inc. operates as a biotechnology company that develops drugs and provides small molecule drugs called Molecular Gates which eliminate extracellular proteins. The company was Co-founded by Jordi Mata (CEO), Pat Sharp, and Raman Talwar (CTO). In November 2025, Gate Bioscience, Inc. raised USD 65 million in series B funding led by new investor Forbion, with participation from another new investor Lilly Ventures. Returning investors Versant Ventures, Andreessen Horowitz, GV, and ARCH Venture Partners also participated in the round.

The firm develops small molecule therapeutics named molecular gates which are small molecule drugs that eliminate harmful extracellular proteins at their origin, inside cells, and prevent them from emerging to cause disease.

The firm plans to use the November 2025 funding to move its main molecular gate programs into clinical testing and expand research on new targets.

## Funding rounds

- Series B, Nov 13, 2025, $65M — ARCH Venture Partners, Versant Ventures, Lilly Ventures, Forbion, GV, Andreessen Horowitz
- Series A, Nov 1, 2023, $60M — ARCH Venture Partners, Versant Ventures, GV, Andreessen Horowitz

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series A, Series B
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B